Stock Market News
Hikma FY numbers hit by US impairment charge
A $920m impairment charge on Hikma Pharmaceuticals' West-Ward Columbus business led to the company reporting a hefty $738m full year pre-tax loss on Wednesday.
This compares with a profit of $210m a year earlier. Revenue was flat $1.94bn.
Hikma blamed "intense" pricing pressure and "the increasingly competitive dynamics of the US market" for the hit on its generics business.
"This was further impacted by the delay in approval for our generic version of Advair Diskus," the company said.
Hikma said it expected lower revenues and profitability from newly launched products as well as higher price erosion on its currently marketed portfolio.
"The outlook for West-Ward Columbus revenue and profitability over the medium term is lower than previously expected," the company said.
Hikma reported a basic loss per share of 351.3 cents, compared to earnings per share of 66.5 cents in 2016. The full year dividend was lifted to 34 cents a share, up from 33 cents.
The company said it expected injectables revenue in 2018 to be in the range of $750m - $800m, as increased competition in the US is offset by new launches and continued growth in the Middle East & North Africa and Europe.
It added that it expected generics revenues in 2018 to be $550m - $600m and core generics operating margin in the low single digits before adjustments.
This compares with a profit of $210m a year earlier. Revenue was flat $1.94bn.
Hikma blamed "intense" pricing pressure and "the increasingly competitive dynamics of the US market" for the hit on its generics business.
"This was further impacted by the delay in approval for our generic version of Advair Diskus," the company said.
Hikma said it expected lower revenues and profitability from newly launched products as well as higher price erosion on its currently marketed portfolio.
"The outlook for West-Ward Columbus revenue and profitability over the medium term is lower than previously expected," the company said.
Hikma reported a basic loss per share of 351.3 cents, compared to earnings per share of 66.5 cents in 2016. The full year dividend was lifted to 34 cents a share, up from 33 cents.
The company said it expected injectables revenue in 2018 to be in the range of $750m - $800m, as increased competition in the US is offset by new launches and continued growth in the Middle East & North Africa and Europe.
It added that it expected generics revenues in 2018 to be $550m - $600m and core generics operating margin in the low single digits before adjustments.
Related share prices |
---|
Hikma Pharmaceuticals (HIK) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price